


What is claimed is:

1. A compound of formula (I)



5 wherein,

A is S, O, N, or CH;

B is S, O, N, or CH;

10 R¹ and R² are the same or are different and are C₁₋₈ alkyl, C₂₋₈ alkylene, C₃₋₈ cycloalkyl, aryl, heteroaryl, heterocycloalkyl, C₃₋₆ cycloalkylaryl, or heterocycloaryl; wherein said alkyl, alkylene, cycloalkyl, aryl, heteroaryl, heterocyclyl, cycloalkylaryl, or heterocycloaryl are unsubstituted or substituted by one or more groups selected from the group consisting of halogen, C₁₋₈ alkyl, C₁₋₈alkoxy, C₁₋₈thioalkoxy, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, CF₃, SCF₃, NHC(O)_nR⁵, S(O)_mR⁵, S(O)₂NR⁵R⁶, C(S)NR⁵R⁶, CONR⁵R⁶, C(O)_nR⁵;

15 n is 0, 1 or 2;

m is 0, 1 or 2;

R⁵ is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C₁₋₈alkoxy, aryl, heteroaryl, halogen, NO₂, CN, N₃, SCF₃, and CF₃;

20 R⁶ is hydrogen, alkyl, aryl, alkylaryl, heterocycloalkyl, or heteroaryl and is unsubstituted or substituted by one or more groups selected from the group consisting of alkyl, C₁₋₈alkoxy, aryl, heteroaryl, halogen, NO₂, CN, N₃, SCF₃, and CF₃, or when R¹ and/or R² contains S(O)₂NR⁵R⁶, CONR⁵R⁶, or C(S)NR⁵R⁶, then R⁵R⁶ together with the nitrogen may form a heterocyclic ring; or

25 a pharmaceutically acceptable salt or solvate thereof.

2. A compound of claim 1 wherein in formula (I) R¹ and R² are independently a C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or C₁₋₆ alkylaryl as defined within and A is S and B is N.
- 5 3. A compound of claim 1 wherein in formula (I) R¹ is a C₃₋₆ cycloalkyl and R² is an C₁₋₆ alkyl as defined herein and A is S and B is N.
4. A compound of claim 1 which is
3-amino-5,7-dibutylisothiazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-dione, and
10 3-amino-7-butyl-5-cyclopentylisothiazolo[3,4-*d*]pyrimidine-4,6(5*H*,7*H*)-dione;
or
a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 in admixture with a pharmaceutically acceptable excipient.
- 15 6. A method for the prophylaxis of or for treating osteoporosis in a mammal comprising administering a effective amount of a compound of formula (I) according to claim 1 either neat or in admixture with a pharmaceutically acceptable excipient.